Categories: News

diaTribe Convenes International Consensus to Guide Diabetes Technology Use During Pregnancy

Expert recommendations provide crucial guidance to leverage CGM and AID during pregnancy.

- Advertisement -

SAN FRANCISCO, Jan. 12, 2026 /PRNewswire/ — The diaTribe Foundation announces the publication of the first international consensus statement on the use of continuous glucose monitoring (CGM) and automated insulin delivery (AID) during pregnancy. Published in The Lancet Diabetes & Endocrinology, the document aims to standardize care, improve outcomes, and ease the daily burden of managing type 1 (T1D), type 2 (T2D), and gestational diabetes (GDM) during pregnancy.

- Advertisement -

Managing diabetes is exceptionally challenging during pregnancy due to hormonal shifts and narrow glucose targets. As CGM and AID become standard of care in diabetes for their ability to improve management, many enter pregnancy already relying on these technologies or adopt them to help navigate this demanding time.

- Advertisement -

Despite growing use, application of technology has remained disjointed in pregnancy due to a lack of detailed clinical guidance, particularly for T2D and GDM. “Application of Continuous Glucose Monitoring and Automated Insulin Delivery Technologies for Pregnant Women with Type 1 Diabetes, Type 2 Diabetes or Gestational Diabetes Mellitus” was developed by experts across six continents to address this gap.

- Advertisement -

“It is absolutely possible to have a safe and healthy pregnancy with diabetes, and technologies can help—but these tools are often underutilized due to limited research, few devices approved for use in pregnancy, and a lack of clear guidance,” said Dr. Katrien Benhalima, endocrinologist and chair of the expert author group. “Publishing this consensus is a key step to ensuring that maternal healthcare for people with diabetes continues to improve as technologies evolve.”

- Advertisement -

The paper provides 14 specific recommendations, including:

- Advertisement -
  • Guidance on picking AID systems and adapting settings to meet pregnancy-specific physiological needs, including detailed charts with device-specific recommendations
  • Considerations for technology use during preconception, pregnancy, labor and delivery, and the immediate postpartum period
  • CGM time in range targets specifically for T2D and GDM, expanding upon previous standards set for T1D.

The consensus aims to support key members of the pregnancy care team who may be less familiar with diabetes technologies, including primary care and obstetrics providers, through recommendations based on the latest evidence and clinical experience. By confirming these technologies can be safely used during pregnancy, the authors also hope to increase device access and user confidence.

- Advertisement -

This initiative was led by The diaTribe Foundation and strengthened by input from 25 leading global bodies, including the American College of Obstetricians and Gynecologists, Breakthrough T1D, European Association for the Study of Diabetes, and World Organization of Family Doctors.

- Advertisement -

The diaTribe Foundation is dedicated to improving the lives of people with diabetes and advocating for action. We ensure that people have the resources and education needed to thrive with diabetes, bring people with diabetes to the conversation on regulatory issues, connect the field and the diabetes community, and change the narrative around diabetes.

- Advertisement -

Endorsing organizations:
ADJ Diabetes Brazil
Advanced Technologies & Treatments for Diabetes
American Association of Clinical Endocrinology
American College of Diabetology
American Pharmacists Association
Association of Diabetes Care & Education Specialists
Australasian Diabetes in Pregnancy Society
Australian Diabetes Society
Australian Diabetes Educators Association
Brazilian Diabetes Society
Breakthrough T1D
Centre for Chronic Disease Control (India)
Diabetes Australia
Diabetes India
European Association for the Study of Diabetes
European Board and College of Obstetrics and Gynaecology
Indian College of Obstetricians and Gynaecologists
International Association of Diabetes and Pregnancy Study Groups
International Diabetes Federation
International Federation of Gynaecology and Obstetrics
Japan Diabetes Society
Research Society for the Study of Diabetes India
Society for Obstetric Medicine India
World Organization of Family Doctors

- Advertisement -

Supported by the American College of Obstetricians and Gynecologists

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/diatribe-convenes-international-consensus-to-guide-diabetes-technology-use-during-pregnancy-302658755.html

- Advertisement -

Recent Posts

Dassault Systmes CEO Pascal Daloz becomes also Chairman of the Board of Directors of Dassault Systmes

Press ReleaseVELIZY-VILLACOUBLAY, France — February 21, 2026 Dassault Systèmes’ CEO Pascal Daloz becomes also Chairman…

6 hours ago

Weaviate Launches Agent Skills to Empower AI Coding Agents

Amsterdam, Netherlands, Feb. 21, 2026 (GLOBE NEWSWIRE) -- February 20, 2026 – Weaviate, the leading…

6 hours ago

Seedance2ai.online Launches All-in-One Seedance 2.0 Video Creation Platform With Free Tier for Global Creators

LOS ANGELES, CA, Feb. 21, 2026 (GLOBE NEWSWIRE) -- Seedance2ai.online today announced the public launch…

6 hours ago

Amdavad 2030 Opens Doors to Global Business Opportunities

West Midlands Mayor Leads Strategic UK Delegation to Translate Sporting Ambition into Long-Term Economic PartnershipsAHMEDABAD,…

10 hours ago

Thermobalancing therapy emerges as drug-free option for BPH, chronic prostatitis, back pain and kidney stones

Oxford, UK, Feb. 21, 2026 (GLOBE NEWSWIRE) -- Therapeutic Dr Allen’s Devices are designed to…

11 hours ago

Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option

February 20, 2026 15:10 ET  | Source: Eupraxia Pharmaceuticals Inc. VICTORIA, British Columbia, Feb. 20,…

11 hours ago